Search - tctmd.com

Displaying 41 - 60 of 66

Sort: Relevancy | Date

News Conference News

‘Healing’ Stent Noninferior to Permanent-Polymer Device: PIONEER III

Shelley Wood

November 19, 2020

News Conference News TCT 2020

EXAMINATION Surprise: Few Late Event Gaps Between DES and BMS in STEMI

L.A. McKeown

October 22, 2020

News Conference News TCT 2020

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

Shelley Wood

October 17, 2020

In-Stent Restenosis Accounts for 10% of All PCIs, Contemporary National Analysis Shows

News Daily News

In-Stent Restenosis Accounts for 10% of All PCIs, National Analysis Shows

L.A. McKeown

September 24, 2020

News Conference News ESC 2020

In Long-term, Real-world Data, CABG Bests PCI for Diabetic Patients With MVD

Yael L. Maxwell

September 01, 2020

News Daily News

Analysis Supports Short DAPT Followed by P2Y12 Inhibitor Monotherapy After DES PCI

L.A. McKeown

August 10, 2020

News Daily News

Polymer-Free DES Hold No Long-term Advantage: ISAR-TEST-5

Michael O'Riordan

July 07, 2020

News Daily News

Clopidogrel Holds Advantage in Older NTSE ACS Patients: POPular AGE Published

Michael O'Riordan

April 27, 2020

News Daily News

Meta-analysis Questions PCI vs CABG in Women With Multivessel Disease

Shelley Wood

February 27, 2020

News Conference News CRT 2020

BIOFLOW V: Orsiro Bests Xience at 3 Years for TLF, Late Stent Thrombosis

L.A. McKeown

February 25, 2020

News Daily News

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

Michael O'Riordan

February 10, 2020

News Conference News VIVA 2019

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

L.A. McKeown

November 06, 2019

News Daily News

German Analysis Supports Long-term Safety of Paclitaxel-Based Therapies

L.A. McKeown

October 09, 2019

News Conference News TCT 2019

IVUS-XPL at 5 Years Shows Durability of Imaging Guidance in PCI

Caitlin E. Cox

October 08, 2019

News Conference News TCT 2019

PICCOLETO II: More Support for DCB Safety and Efficacy in Small Coronaries

L.A. McKeown

October 04, 2019

News Conference News ESC 2019

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

Caitlin E. Cox

September 10, 2019

News Conference News ESC 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

Todd Neale

September 03, 2019

News Opinion Off Script

Off Script: Through ‘Paclitaxelgate,’ Some Upsides to Uncertainty

Sahil Parikh, MD

July 29, 2019

News Conference News EuroPCR 2019

Daring to Dream: New BRS Data Hint at Low MACE Rates at 2 and 3 Years

Michael O'Riordan

May 27, 2019

News Conference News EuroPCR 2019

Firehawk Stent Still Holds Up Well to Xience at 2 Years: TARGET All Comers

Caitlin E. Cox

May 23, 2019

Advertisement

‘Healing’ Stent Noninferior to Permanent-Polymer Device: PIONEER III

EXAMINATION Surprise: Few Late Event Gaps Between DES and BMS in STEMI

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

In-Stent Restenosis Accounts for 10% of All PCIs, National Analysis Shows

In Long-term, Real-world Data, CABG Bests PCI for Diabetic Patients With MVD

Analysis Supports Short DAPT Followed by P2Y12 Inhibitor Monotherapy After DES PCI

Polymer-Free DES Hold No Long-term Advantage: ISAR-TEST-5

Clopidogrel Holds Advantage in Older NTSE ACS Patients: POPular AGE Published

Meta-analysis Questions PCI vs CABG in Women With Multivessel Disease

BIOFLOW V: Orsiro Bests Xience at 3 Years for TLF, Late Stent Thrombosis

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

German Analysis Supports Long-term Safety of Paclitaxel-Based Therapies

IVUS-XPL at 5 Years Shows Durability of Imaging Guidance in PCI

PICCOLETO II: More Support for DCB Safety and Efficacy in Small Coronaries

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

Off Script: Through ‘Paclitaxelgate,’ Some Upsides to Uncertainty

Daring to Dream: New BRS Data Hint at Low MACE Rates at 2 and 3 Years

Firehawk Stent Still Holds Up Well to Xience at 2 Years: TARGET All Comers

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content